000153632 001__ 153632
000153632 005__ 20251017144554.0
000153632 0247_ $$2doi$$a10.1007/s12094-020-02295-w
000153632 0248_ $$2sideral$$a116844
000153632 037__ $$aART-2020-116844
000153632 041__ $$aeng
000153632 100__ $$aDómine, M.
000153632 245__ $$aSEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
000153632 260__ $$c2020
000153632 5203_ $$aSmall-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15–20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum–etoposide. In stage IIB–IIIC, the recommended treatment is early concurrent chemotherapy with platinum–etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum–etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum–etoposide is the recommended regimen in patients with sensitive relapse (= 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.
000153632 540__ $$9info:eu-repo/semantics/closedAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000153632 590__ $$a3.405$$b2020
000153632 591__ $$aONCOLOGY$$b159 / 241 = 0.66$$c2020$$dQ3$$eT2
000153632 592__ $$a0.902$$b2020
000153632 593__ $$aCancer Research$$c2020$$dQ2
000153632 593__ $$aOncology$$c2020$$dQ2
000153632 593__ $$aMedicine (miscellaneous)$$c2020$$dQ2
000153632 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000153632 700__ $$aMoran, T.
000153632 700__ $$aIsla, D.
000153632 700__ $$aMartí, J. L.
000153632 700__ $$aSullivan, I.
000153632 700__ $$aProvencio, M.
000153632 700__ $$aOlmedo, M. E.
000153632 700__ $$aPonce, S.
000153632 700__ $$aBlasco, A.
000153632 700__ $$aCobo, M.
000153632 773__ $$g22, 2 (2020), 245-255$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X
000153632 85641 $$uhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85079002185&doi=10.1007%2fs12094-020-02295-w&partnerID=40&md5=ed9f62501c3a0c8fdfcc213ec47fe6a9$$zTexto completo de la revista
000153632 8564_ $$s843838$$uhttps://zaguan.unizar.es/record/153632/files/texto_completo.pdf$$yVersión publicada
000153632 8564_ $$s2232017$$uhttps://zaguan.unizar.es/record/153632/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000153632 909CO $$ooai:zaguan.unizar.es:153632$$particulos$$pdriver
000153632 951__ $$a2025-10-17-14:12:36
000153632 980__ $$aARTICLE